The Use of Bioengineered Induced Pluripotent Stem Cell-Derived Human Megakaryocytes to Diagnose and Characterize Platelet Allo-, Auto-, and Iso-Immune Disorders.

Engineering Human Hematopoietic Stem and Progenitor Cells for Antigen Expression in Antigen-Presenting Cells.

The studies characterize human chimerism and therapeutic gene expression in a new model and provide support for the use of HSPC-based gene therapies for immune dysregulation in humans.

Production of Induced Pluripotent Stem Cell-Derived Red Blood Cells.

Protocols to generate developmentally primitive and definitive RBCs from iPSCs are outlined, and methods to perform antibody identification using iPSC-derived RBCs as reagent cells in gel agglutination assays commonly used by blood banks and reference immunohematology laboratories are outlined.

Highly Efficient Derivation of Functional Human-Induced Pluripotent Stem Cell-Derived Macrophages under Serum-Free Conditions to Study Innate Immune Responses

A robust, reproducible, efficient serum-free and feeder-free protocol for generating functional iMacs and characterizing their innate immune properties, providing a versatile model for investigating innate immunity, host-pathogen interactions, and interferon signaling.

A Scalable Stem Cell-derived Erythroid Cell System for the Encapsulation and Delivery of Therapeutic Enzymes: An In Vitro Proof-of-Concept Study.

This study established an iPSC-derived platform for generating ASPG-loaded erythroid cells with favorable carrier properties and evident anti-leukemic activity in vitro, laying a conceptual foundation for future cell therapy manufacturing via optimized terminal maturation.

Induced pluripotent stem cell–derived macrophages (iMacs) in translational medicine: Disease models, drug testing, and therapeutic applications

Examination of Class I HLA-Fc Fusion Proteins in Targeting Cognate Antibody-Producing Cells.

The protocols in this chapter outline the design, production, and evaluation of HLA-Fc proteins, emphasizing their efficacy in vitro and in immunodeficient mouse models, potentially providing new therapeutic approaches for managing HLA-sensitized patients in clinical practice.